Rapid Novor’s EasyM™ is a mass spectrometry-based diagnostic that enables non-invasive, serum-based monitoring of minimal residual disease in multiple myeloma patients. Replacing invasive bone marrow biopsies, EasyM uses de novo protein sequencing and targeted LC-MS for accurate M-protein tracking. By integrating Evosep One and Evotips, the workflow achieves 80% less overhead, 2× throughput, and 30% shorter runtimes with consistent, reproducible results. The system enhances sample stability and supports standardization across instruments. EasyM’s robustness and automation position it as a leading tool for scalable clinical proteomics.

Join for free to read